WO2015130225A1 - Dispositif d'analyse d'urine et réactif sec pour analyse quantitative de l'urine - Google Patents

Dispositif d'analyse d'urine et réactif sec pour analyse quantitative de l'urine Download PDF

Info

Publication number
WO2015130225A1
WO2015130225A1 PCT/SG2014/000269 SG2014000269W WO2015130225A1 WO 2015130225 A1 WO2015130225 A1 WO 2015130225A1 SG 2014000269 W SG2014000269 W SG 2014000269W WO 2015130225 A1 WO2015130225 A1 WO 2015130225A1
Authority
WO
WIPO (PCT)
Prior art keywords
albumin
sample
absorbances
formulation
concentration
Prior art date
Application number
PCT/SG2014/000269
Other languages
English (en)
Inventor
Xiaojun Chen
Yingsong Wang
Pei Shan HO
Xi Er YEO
Original Assignee
Nitto Denko Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP14883985.5A priority Critical patent/EP3111228A4/fr
Priority to AU2014384759A priority patent/AU2014384759B2/en
Priority to CN201480076591.9A priority patent/CN106255887B/zh
Priority to US15/121,808 priority patent/US10436792B2/en
Application filed by Nitto Denko Corporation filed Critical Nitto Denko Corporation
Priority to KR1020207024161A priority patent/KR102301688B1/ko
Priority to KR1020207024160A priority patent/KR102267988B1/ko
Priority to MYPI2016001553A priority patent/MY192493A/en
Priority to JP2016554178A priority patent/JP6490090B2/ja
Priority to KR1020167026791A priority patent/KR102205101B1/ko
Priority to SG11201606798QA priority patent/SG11201606798QA/en
Publication of WO2015130225A1 publication Critical patent/WO2015130225A1/fr
Priority to US16/239,743 priority patent/US10656160B2/en
Priority to US16/239,750 priority patent/US10613097B2/en
Priority to AU2021204418A priority patent/AU2021204418A1/en
Priority to AU2021204516A priority patent/AU2021204516A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/27—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection ; circuits for computing concentration
    • G01N21/272—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection ; circuits for computing concentration for following a reaction, e.g. for determining photometrically a reaction rate (photometric cinetic analysis)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Definitions

  • Urinalysis is a source of information about the anatomy and function of the kidneys and urinary tract. It provides insights into the status of systemic diseases such as diabetes mellitus.
  • test strips, or dipsticks, for urinalysis is widely accepted for health screening purposes because it provides a simple protocol and is very cost-effective.
  • Dipstick urinalysis is convenient, but false-positive and false-negative results can occur due to the discrimination of color change when it is performed by a human eye, such as by a nurse.
  • CKD Chronic Kidney Disease
  • ACR urine albumin creatinine ratio
  • ACR is also a useful parameter to measure for use as a prognosis factor for kidney failure risk. Monitoring the ACR value during treatment is also useful, and a point-of-care device is required to improve patients' Quality of Life (QOL).
  • QOL Quality of Life
  • a urine analyzer is generally a desk-top machine or part of a larger piece of equipment, such as a fully automated blood serum/urine analyzer. Therefore, the accessibility of these quantitative urinalysis units is centralized and people who live in rural areas have limited access to proper diagnostic tests.
  • Urine samples have a large pH variation, and the measurement results are also affected by the temperature of the surroundings (i.e. the testing place).
  • Current quantitative assay methods require sample dilution to remove the interference caused by urine.
  • colorimetric wet reagents for urinalysis are required to be kept in refrigerator, which is not suitable for home or clinical use.
  • a urine sample is diluted with a volume of buffer in addition to a strong acid or a strong alkali.
  • a cooling system is introduced into the device used for analysis, but this cooling system makes the device bulky. The size of the resulting device makes it difficult to transport and renders it unusable in anything other than a clinical laboratory setting.
  • the reagents used in urinalysis may suffer from bubble formation, either occurring during the reaction, or from the addition of the sample to the reagent. This can result in the loss of accuracy due to light scattering.
  • an internal reference table is normally prepared under a range of pH and/or temperature conditions, so as to normalize the data, but it is troublesome to prepare the reference table and there is a limit on how far the normalisation can be taken, depending on the type of interference. Given this, the result is not accurate for all patients.
  • a method of quantitatively determining the concentration of at least one analyte in a sample comprising the steps of: i) (a) adding a portion of the sample to a first analyte assay formulation comprising a first analyte complexing reagent to generate a first analyte sample;
  • analyte assay reference formulation that is identical to the first analyte assay formulation, except that it further comprises a reagent that denatures the analyte or blocks the formation of a complex between the analyte and the first analyte complexing reagent, to generate an analyte reference sample;
  • the at least one analyte is albumin and the method comprises the steps of:
  • albumin assay sample formulation comprising an albumin complexing reagent to generate an albumin sample
  • albumin assay reference formulation that is identical to the albumin assay formulation except that it further comprises an anionic surfactant to generate an albumin reference sample, and determining the concentration of albumin in the sample by measuring the absorbance spectra of the albumin sample and the albumin reference sample, calculating the difference between the absorbance spectra of the albumin sample and the albumin reference sample and comparing the difference spectrum obtained to a predetermined calibration curve of albumin concentration.
  • the at least one analyte is creatinine and the method comprises the steps of adding a portion of the sample to a creatinine assay sample formulation comprising a creatinine complexing reagent to generate a creatinine sample and determining the concentration of creatinine in the sample by measuring the change of the absorbance spectra of the creatinine sample over a period of time, calculating the rate of the absorbance change of the creatinine sample over said period of time and comparing the rate obtained to a pre-determined calibration curve of creatinine concentration.
  • the at least one analyte is albumin and creatinine, the method comprising the steps of:
  • one or more of the formulations may be lyophilised.
  • all of the formulations are lyophilised.
  • the sample is a urine sample.
  • the step of determining the concentration of albumin requires measuring the absorbance spectra:
  • the step of determining the concentration of creatinine requires measuring the rate of absorbance change at 525 nm of the creatinine sample. In yet further embodiments, the step of determining the concentration of creatinine requires measuring the rate of absorbance change at 525 nm of the creatinine sample involves measuring the absorbance during a period of from about 10 seconds up to about 10 minutes. For example, such kinetic measurement starts at 30 seconds and ends at 10 minutes from the addition of the sample to the second assay formulation or the creatinine assay formulation (i.e. the kinetic measurement starts at 1 minute and ends at a time between 5 and 10 minutes from the addition of the sample to the second assay formulation or the creatinine assay formulation).
  • the method may determine the creatinine concentration and the albumin concentration simultaneously.
  • the creatinine sample assay formulation is as defined in the second aspect of the invention.
  • the albumin assay formulation is as defined in the third aspect of the invention.
  • the pre-determined calibration curve of albumin concentration is obtained by a computer-implemented method of generating a calibration curve for use in quantitatively determining the concentration of albumin in a urine sample, the method being defined in the sixth aspect of the invention.
  • a formulation for use in the analysis of the creatinine concentration of a sample comprising:
  • a strong base in a concentration of from about 40 to about 80 g/L; a buffer in a concentration of from about 50 to about 250 g/L;
  • At least one surfactant in a concentration of from about 0.1 to about 20 g/L; and water.
  • the formulation further comprises a compound that reacts with creatinine to generate a creatinine complex.
  • the compound that reacts with creatinine to generate a creatinine complex is picric acid or, more particularly, dinitrobenzoic acid.
  • the concentration of the compound that reacts with creatinine to generate a creatinine complex is from about 1 to about 5 g/L.
  • the at least one surfactant comprises an anionic surfactant in a concentration from about 0.1 to about 10 g/L and a cationic surfactant in a concentration from about 0.1 to about 10 g/L.
  • the ratio of cationic surfactant: anionic surfactant is from 1 :2 to 1 :10 (e.g. from 1:3 to 1:7, such as 1:5).
  • the at least one surfactant comprises a cationic surfactant, it is selected from one or more of the group consisting of cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, dimethyldioctadecyl- ammonium chloride, cetrimonium bromide, dioctadecyldimethylammonium bromide, and hexadecyltrimethylammonium bromide; and/or
  • the at least one surfactant comprises an anionic surfactant, it is selected from one or more of the group consisting of sodium dodecyl sulfate, polystyrene sulfonates, linear alkylbenzene sulfonate, secondary alcohol sulfonate, alcohol olefin sulfonate, and alcohol sulfate; and/or
  • the buffer is selected from one or more of the group consisting of K 2 HP0 4 , Na 2 HP0 4 , and borate; and/or
  • the strong base is NaOH and/or KOH.
  • the formulation for use in the analysis of the creatinine concentration of a sample is lyophilised.
  • the formulation for use in the analysis of the creatinine concentration of a sample further comprises a bulking agent in an amount of from about 1 to about 40 weight% of the formulation, optionally wherein the bulking agent is selected from one or more of the group consisting of sugar-mannitol, lactose, and trehalose.
  • the formulation for use in the analysis of the creatinine concentration of a sample the concentration ratio of the buffer:strong base in the formulation is from 0.5:1 to 2.5:1, such as from 1 :1 to 1.5:5, such as 1.25:1.
  • a formulation for use in the analysis of albumin concentration of a sample comprising:
  • a compound that reacts with albumin to generate an albumin complex in a concentration of from about 0.1 to about 1.5 g/L;
  • a strong base in a concentration of from about 10 to about 50 g/L; a buffer in a concentration of from about 50 to about 250 g/L; a first non-ionic surfactant in a concentration of from about 1 to about 20 g/L; a preservative in a concentration of from about 0.1 to about 3 g/L; and water.
  • the formulation further comprises an anionic surfactant.
  • the anionic surfactant is present in from about 0.1 to 5 weight% of the formulation.
  • the anionic surfactant is selected from one or more of the group consisting of sodium dodecyl sulfate, polystyrene sulfonates, linear alkylbenzene sulfonate, secondary alcohol sulfonate, alcohol olefin sulfonate, and alcohol sulfate.
  • the compound that reacts with albumin to generate an albumin complex is bromocresol green.
  • the buffer is selected from one or more of the group consisting of ⁇ -(1 ⁇ - acetamido)-2-aminoethanesulfonic acid, sodium acetate, N-(2-acetamido)- iminodiacetic acid, 2-amino-2-methyl-1-propanol, 2-amino-2-methyl-1 ,3-propanediol, N-(1 ,1-dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid, N,N-bis-(2- hydroxyethyI)-2-aminoethane-sulfonic acid, sodium hydrogen carbonate, N,N-bis-(2- hydroxyethyl)-glycine, bis-(2-hydroxyethyl)-imino-tris-(hydroxymethyl)-methane, 1 ,3- bis-[tris-(hydroxymethyl)-methylamino]-propane, 3-cyclohexylamino)
  • the first non-ionic surfactant is selected from one or more of the group consisting of brij, polypropylene glycol), polyethylene glycol hexadecyl ether, triton X-100, tween, ZonylTM FSN fluorosurfactant, ALKANOLTM 6112 surfactant, polyethylene glycol, optionally wherein the first non-ionic surfactant is brij; and/or
  • the preservative is selected from one or more of the group consisting of sugar, sorbic acid, benzoic acid, calcium propionate, sodium nitrite, sodium azide, sulfites, disodium EDTA and antioxidants; and/or
  • the strong base is NaOH and/or KOH.
  • the formulation for use in the analysis of the albumin concentration (and the reference sample) may be lyophilised.
  • the formulation may further comprise a second non- ionic surfactant in an amount of from about 10 to about 200 g/L of the formulation.
  • the second non-ionic surfactant may be selected from one or more of the group consisting of brij, polypropylene glycol), polyethylene glycol hexadecyl ether, triton X-100, tween, ZonylTM FSN fluorosurfactant, ALKANOLTM 6112 surfactant, polyethylene glycol, provided that the first and second non-ionic surfactants are different to each other, optionally wherein the second non-ionic surfactant is polyethylene glycol.
  • a method of preparing the lyophilised formulation for use in the analysis of creatinine concentration of a sample as described in respect of the second aspect of the invention or the lyophilised formulation for use in the analysis of albumin concentration of a sample as described in the third aspect of the invention, comprising the steps of:
  • the container is selected from the group consisting of an eppendorf tube, a 96-well plate, a commercial cuvette or a cuvette adapted for use with a device comprising a contact image sensor module.
  • the method may further comprise storing the container holding the lyophilised formulation away from light, oxygen and moisture.
  • kit of parts comprising:
  • each lyophilised formulation in the kit of parts, may be individually contained in an eppendorf tube, a cuvette, a cuvette adapted for use with a device comprising a contact image sensor module, or separate wells in a 96-well plate.
  • the formulations are stored away from light, oxygen and moisture.
  • a computer-implemented method of generating a calibration curve for use in quantitatively determining the concentration of albumin in a urine sample comprising the steps of:
  • first absorbance data representing albumin-free sample absorbances and albumin-free reference absorbances for a plurality of albumin-free urine samples
  • albumin-free sample absorbances comprise absorbances for respective first portions of the albumin-free urine samples in the presence of an albumin-complexing reagent
  • albumin-free reference absorbances comprise absorbances for respective second portions of the albumin-free urine samples in the presence of the albumin-complexing reagent, and additionally in the presence of an albumin-denaturing reagent or a reagent that blocks the formation of a complex between albumin and the aibumin-complexing reagent
  • the adjusted reference absorbances are calculated according to a * A R * + b, where A R * are the reference absorbances.
  • Figure 12 Calibration curve of BCG dry-reagent with real urine sample before data processing
  • the reagents may be suitable for use with a point-of-care analysis system that can simultaneously measure a number of analytical samples.
  • such a system may comprise the use of a contact image sensor (CIS) module having a light emitting diode (LED) to emit light, the wavelength of the light is preconfigured to match the absorption wavelength of the reaction product of a urinalysis reagent and target analyte, an optical cuvette having the reflective surface at the far side of the cuvette from the CIS module, a freeze-dried urinalysis reagent being disposed in the optical cuvette, a urine distribution structure having reservoir to distribute sample urine into individual optical cuvette and having solution stopping structure to control the volume of distributed solution separately.
  • Chronic Kidney Disease (CKD) can be diagnosed in its early stages by measuring microalbuminuria.
  • Such tests can be performed by determining urine microalbuminuria and creatinine concentrations and their corresponding albumin/creatinine ratio (ACR). While the tests used herein may be used to analyse a urine sample, the tests are also suitable for analysing samples from other sources (e.g. saliva, blood etc). As such, the term “urine microalbuminuria” may be replaced throughout the specification by the term "albumin”.
  • BCG Bromcresol green
  • DNBA 3,5-dinitrobenzoic acid
  • Microalbuminuria present in a urine sample reacts with BCG to form a colored complex (Fig.1).
  • the intensity of the color measured at a wavelength of 625 nm, is directly proportional to the microalbuminuria concentration in the urine sample.
  • microalbuminuria assay two types of wet or, more particularly, dry reagents are prepared for sampling and referencing.
  • the mixtures of the dry reagents (sampling and referencing) and the urine sample are measured concurrently by colorimetric assay.
  • the sampling reagent is used to measure the intensity of the color obtained by the BCG-albumin complex.
  • the referencing reagent is used to reduce or remove pH and temperature effects and interference by applying a protein denaturing method to the urine sample. That is, the microalbuminuria assay applies a protein denaturing method, where the dry reagent for referencing contains a surfactant to denature albumin, so that denatured albumin doesn't react with the BCG present in the referencing reagent.
  • Creatinine present in a urine sample reacts with DNBA in alkaline medium to form a purple- red complex (Fig. 2).
  • the rate of complex formation at wavelength of 525 nm is directly proportional to the concentration of creatinine in the urine sample.
  • DNBA may be replaced by picric acid.
  • the creatinine assay only uses a sampling reagent for measuring creatinine.
  • the creatinine sampling reagent applies a buffer addition method to minimise the interference from urine pH, while the temperature effect is compensated by a temperature factor in the calibration curve and the urine background effect is eliminated by measuring the rate of complex formation.
  • Current, devices are tailored so as to operate within the reaction parameter of conventional formulations. This may result in a more complicated automated device, as differing sensors may need to be used to analyse the reaction products of the different reagents used to detect analytes in urine (e.g. colourimetric analysis).
  • a buffer addition method is applied to the DNBA dry-reagent to remove the effect of urine pH.
  • DNBA reacts with creatinine under alkaline conditions, and a purple-colored complex is generated.
  • the sampling reagent contains DNBA, a strong base, a buffer, a bulking agent, an anionic surfactant and a cationic surfactant.
  • the specific chemicals used can be chosen from the list below (Table A), and the concentration of each chemical can be within the specified range.
  • Anionic surfactant especially anionic sulphated/sulphonated surfactant; Sodium dodecyl sulfate (SDS), Polystyrene sulfonates (PSS), linear alkylbenzene sulfonate (LAS), secondary alcohol sulfonate, alcohol olefin sulfonate, alcohol sulfate.
  • SDS sodium dodecyl sulfate
  • PSS Polystyrene sulfonates
  • LAS linear alkylbenzene sulfonate
  • secondary alcohol sulfonate alcohol olefin sulfonate
  • alcohol sulfate especially anionic sulphated/sulphonated surfactant.
  • CPC Cetylpyridinium chloride
  • BAC Benzalkonium chloride
  • BZT Benzethonium chloride
  • the ratio of buffer and sodium hydroxide may be selected to suit the analytical device. This enables the device to produce a more accurate reading.
  • the concentration ratio (in Molar) of the buffer:strong base may be from 0.5:1 to 3.2:1 , such as from 0.8:1 to 2.5:1 (e.g. from 1.5:1 to 2.5:1), such as from 1 :1 to 1.5:1 (e.g. 1.25:1).
  • a bufferstrong base ratio of less than 0.5:1 may result in the complex formation becoming too quick to accurately measure the rate of its formation.
  • a cationic surfactant that includes a quarternary ammonium moiety is useful in controlling the formation of bubbles when used in combination with an anionic surfactant as a solvation assistant. This is because the quarternary ammonium surfactant is not able to dissolve in sufficient quantity in the buffered solution without a solvation aid (e.g. an anionic surfactant), while the anionic surfactant does not affect bubble formation when used alone.
  • a solvation aid e.g. an anionic surfactant
  • the ratio of the cationic surfactant: anionic surfactant may be from 1:2 to 1:10, such as from 1:3 to 1:7 or, more particularly, 1:5.
  • a protein denaturing method is applied for the BCG dry-reagent to remove the interference from the urine components, such as urine pH, sample temperature and urine background! Albumin reacts with BCG and the color changes, but denatured albumin does not react with BCG and the color remains the same.
  • the 1 st reagent is for sampling and the 2 nd reagent is for referencing. Both reagents contain the same concentrations of BCG, Strong base, buffer, non-ionic surfactant and preservative. However, only the 2 nd reagent contains an anionic surfactant to denature albumin in the reference sample.
  • the chemicals can be chosen from the list provided below (Table B), and the concentrations can be within the specified range.
  • Non-ionic surfactant 1 1-20 g/L 1-20 g/L
  • Non-ionic surfactant Poly(propylene glycol) (PPG), Polyethylene glycol hexadecyl ether (Brij), Triton X-100, Tween, Zonyl®FSN fluorosurfactant, ALKANOL®6112 surfactant, Polyethylene Glycol (PEG).
  • PPG Poly(propylene glycol)
  • Brij Polyethylene glycol hexadecyl ether
  • Triton X-100 Triton X-100
  • Tween Triton X-100
  • Tween Tritonyl®FSN fluorosurfactant
  • ALKANOL®6112 surfactant Polyethylene Glycol (PEG).
  • Anionic surfactant Sodium dodecyl sulfate (SDS), Polystyrene sulfonates (PSS), linear alkylbenzene sulfonate, (LAS), secondary alcohol sulfonate, alcohol olefin sulfonate, alcohol sulfate.
  • SDS Sodium dodecyl sulfate
  • PSS Polystyrene sulfonates
  • LAS linear alkylbenzene sulfonate
  • secondary alcohol sulfonate alcohol olefin sulfonate
  • alcohol sulfate Method of preparing dry reagent (Fig. 3)
  • the prescribed chemical components are mixed and filtered through a 0.45pm cellulose acetate filter disk.
  • the filtered mixture is dispensed into an appropriate sample well by pipette or dispenser.
  • the sample well can be an eppendorf tube, a 96 well plate, a commercial cuvette, or any other equivalent reagent holder.
  • the sample well may be a cuvette cartridge (102) as depicted in Figure 4.
  • the sample well is inserted into a freeze-dryer and freeze-dried under a specific profile, which consists of freezing, annealing, freezing, primary drying and secondary drying processed.
  • the freeze-drying process can be performed under moisture-less conditions to avoid contact with moisture.
  • the use of other reagent holders may require optimization of the primary drying duration (e.g. extension of duration).
  • freeze-drying profile and the range of parameters is provided in the table below. These conditions may be particularly suited to the cuvette cartridge depicted in Figure 4.
  • the dried reagent should be stored in the dark and in dry conditions to prevent light, moisture and oxygen exposure.
  • the dried reagent can be packed into moisture barrier bags and vacuum sealed in a glove box (i.e. under an inert atmosphere). If necessary, a desiccant or an antioxidant can be inserted into the package.
  • Cuvette cartridge, introduction device and assay method
  • a cuvette cartridge system and sample introduction device can be utilized with the dry reagent (e.g. as depicted in Figures 4 to 7).
  • the width of the cartridge may be calculated based on the path length of each analyte.
  • Volume can be the same in each cuvette cartridge (102) when the assay is for multiple analytes.
  • the volume can be 0.5 mL to 5 ml_, preferably 1 mL.
  • the cuvette width can be 5 mm for the Albumin assay, and 2 mm for the creatinine assay.
  • the cuvette cartridge (102) can be made of transparent material, such as PM MA (Poly-methyl methacrylate, PC (Polycarbonate), COC (Cyclic Olefin Copolymer). To block stray light, the color may be black.
  • Liquid reagent is dispensed into a cuvette cartridge (102) by dispenser (e.g. a Musashi Dispenser), and freeze-dried by a Freeze-dryer (VirTis Advantage Plus Freeze-dryer). For example, using the method of preparing and storing the dry reagent used above. It will be appreciated that the reagent may be used in "wet" form, that is, without freeze-drying.
  • the cuvette cartridge (102) is transferred into a cuvette holder (100; Fig. 4).
  • the cuvette holder (100) can hold 4 cuvette cartridges (102).
  • 4 cuvettes can be arranged in 2 lines separated by a light blocking structure (101).
  • 2 cuvette cartridges (102) can be used for one analyte
  • the other 2 cuvette cartridges can be used for the other analyte.
  • two optical modules (700) can be arranged to each side of the cuvette holder (100). It will be appreciated that the cuvette holder (100) also serves to maintain the distance between the cuvette (102) and the light module (700), so that a certain path length is maintained during sample measurement.
  • Urine is collected from a subject into a collection cup, sucked up into a syringe and introduced into a sample well (501 ; Fig. 5) through a sample introduction port (500) in a sample well cover (502). Urine is dispensed into each cuvette (102) through a sample introduction hole (600; Fig. 6). Urine and dry reagent are mixed in the cuvette cartridge by shaking, magnetic stirring, vibration, sonication, or in any other equivalent way. Optical measurement is performed using one or more optical modules (700; Fig. 7). As shown in Fig.8, the absorbance value is measured for each cuvette, and, where necessary, the difference between the sample and reference is calculated. By utilizing a calibration curve which has been prepared beforehand, the analyte concentration can be calculated, and the albumin to creatinine ratio can be calculated thereafter. [Alb] 25°C 28°C 31°C 34°C
  • a s - A R ⁇ A* C +B (1)
  • a s refers to the sampling reagent
  • a R refers to the referencing reagent
  • C A i b refers to the concentration of albumin
  • a and B are constants. While the resulting calibration curve was found to be accurate for subjects with medium to high levels of albumin (e.g. 30- 300 mg/L), it was found that the results obtained for low levels of albumin (e.g. 0-30 mg/L) could vary significantly. These results are depicted in Fig. 12 and in Table 5 (i.e. the unspiked urine samples should have an average concentration of around 0 mg/L). It is believed that this inaccuracy is caused by a urine matrix side-effect, which results in greater variation at lower concentrations.
  • equation (4) is obtained.
  • equation (4) can be rewritten as equation (5): A $ A ⁇ —A* ⁇ C kVo C Alb ) ⁇
  • the normalised curve calibration curve of Fig.14 is more accurate across the concentration range, and especially at low concentrations of albumin. This is illustrated in Table 6.
  • the above-described calibration process may be implemented as one or more software modules executed by a standard computer system such as an Intel IA-32 based personal computer system, as shown in Figure 16.
  • a standard computer system such as an Intel IA-32 based personal computer system, as shown in Figure 16.
  • ASICs application-specific integrated circuits
  • FPGAs field programmable gate arrays
  • a system 1600 for generating a calibration curve for use in quantitatively determining the concentration of albumin in a urine sample executes a calibration process, as described above, which is implemented as one or more software components 1630 stored on non-volatile (e.g., hard disk, solid-state drive, or flash memory) storage 1602 associated with a standard computer system.
  • the system 1600 includes standard computer components, including random access memory (RAM) 1604, at least one processor 1606, and external interfaces 1608, 1610, 1612, all interconnected by a bus 1614.
  • RAM random access memory
  • the external interfaces include universal serial bus (USB) interfaces 1608, at least one of which is connected to a keyboard 1616 and a pointing device such as a mouse 1618, a network interface connector (NIC) 1610 which can be used to connect the system 1600 to a communications network such as the Internet, and a display adapter 1612, which is connected to a display device such as an LCD panel display 1620.
  • USB universal serial bus
  • NIC network interface connector
  • the system 100 also includes a number of standard software components, including an operating system 1628 such as Linux or Microsoft Windows, and a statistical software package 1629 such as Matlab or R.
  • the system 1600 stores, on non-volatile storage 1602, absorbance data 1640, which comprise first absorbance data representing the albumin-free sample and reference
  • the absorbance data 1640 may be stored from previous experiments, or may be obtained in real time from absorbance measurements carried out on albumin-free and spike-in samples using optical modules 700 and communicated to system 1600 via NIC 1610, for example.
  • the software components 1630 may comprise a first fitting component configured to computationally fit, using statistical software package 1629 for example, the functional relationship described in Eq. (6) between the albumin-free sample absorbances and the albumin-free reference absorbances to obtain adjustment parameters a and b.
  • a s - (a * A R + b) A * C using the calibration parameters a, b and A obtained by the calibration software components 1630 of system 1600.
  • Fig. 15 shows the calibration curve for the creatinine assay.
  • the kinetics of the DNBA/creatinine reaction is measured and a calibration curve for creatinine is generated by plotting the rate of reaction vs. creatinine concentration.
  • Creatinine standards are prepared with artificial or pooled urine and certain concentration of creatinine.
  • the creatinine assay requires 5 min to 10 min and microalbuminuria assay requires around 5 min.
  • a kinetic measurement may start from the time that the sample is added to the creatinine assay formulation, or that the measurement may be delayed (e.g. for 5 seconds, 10 seconds, 30 seconds, 1 minute, 2 minutes or 5 minutes) before the kinetic measurements are started. Therefore, the actual window of sensing time where the measurements are taken may be from 1 minute to 10 minutes.
  • the time interval for data acquisition during the kinetic measurements in the creatinine assay may be from 0.1 seconds to 15 seconds (e.g. 5 seconds).
  • Total assay time from sampling to provide ACR value can be less than 10min, and this is a rapid measurement. Advantages of dry reagent assay system
  • the dry-reagents are very easy to be reconstituted by addition of a urine sample.
  • the reagents allow for a one-step sensing protocol, which significantly improves user- friendliness.
  • the formulations prevent the formation of air-bubbles adhered to the surface of the cuvette wall upon the reconstitution of the dry-reagent with a urine specimen, allowing direct optical measurement. That is, the formulation disclosed herein allows for fast optical measurement, without having to remove bubbles from the solution (if even possible), the removal of bubbles from the reconstituted formulation in urine also allows for greater accuracy of measuring absorbance, as it reduced light scattering.
  • the formulations discussed herein are easy to store and transport, as compared with the wet-reagents.
  • a buffer addition method and/or a protein denaturing method can also be applied for urinary components other than creatinine or albumin.
  • urinary components include, but is not limited to, water, ions (e.g., sodium, potassium, chloride, phosphoric acid, phosphorus, sulfur, bromide, fluoride, iodide, calcium, magnesium, iron, lead, mercury, etc.), proteins (e.g.
  • haptoglobin transferrin, immunoglobulin, lactadehydrogenase, gamma-glutamyl transferase, alpha amylase, uropepsinogene, lysozyme, urokinase, etc.
  • sugars e.g., glucose, phenylpyruvate.arabinose, xyloseribose, fucose, rhammose, ketopentose, galactose, mannose, fructose, lactose, sucrose, fucosylglucose, raffinose, etc.
  • amino acids e.g., alanine, carnosine, glycine, histidine, leucine, lysine, methionine, phenylalanine, serine, tyrosine, valine, hydroxyloproline, galactosylhydroxylyzine, xylosylserine, etc.
  • the sensing temperature can be from 15°C to 40°C.
  • the dry reagent can be packed within a moisture-proof bag and stored at room temperature for a year at least.
  • the dry reagent system includes a reagent for reference sample to lessen the effect of pH, temperature and interferences.
  • a reagent for reference sample to lessen the effect of pH, temperature and interferences.
  • creatinine, albumin or other target assay to include chemical with buffering effect into reagent for reference sample is effective.
  • albumin assay denaturing albumin by surfactant in reference sample is highly effective to measure reference sample.
  • wet reagents may be used instead of dry reagents.
  • the wet reagent for measuring creatinine doesn't require a bulking agent
  • the wet reagent for measuring microalbuminuria doesn't require non-ionic surfactant 2 as shown in Tables 7 and 8 below.
  • Non-ionic surfactant 1 1-20 g/L 1-20 g/L
  • Anionic surfactant (1-50 g/L)
  • microalbuminuria/creatinine assay can be separated. That is, the microalbuminuria assay may be run alone or the creatinine assay may also be run alone.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plasma & Fusion (AREA)
  • Mathematical Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Optical Measuring Cells (AREA)

Abstract

L'invention concerne un procédé de détermination quantitative de la concentration d'au moins un analyte dans un échantillon, le procédé comprenant les étapes suivantes : (i) l'ajout d'une partie de l'échantillon à une première formulation de dosage d'analyte et à une formulation de référence de dosage d'analyte pour générer un premier échantillon d'analyte et un échantillon de référence d'analyte et la détermination de la concentration du ou des analytes se trouvant dans l'échantillon et/ou (ii) l'ajout d'une partie de l'échantillon à une seconde formulation de dosage d'analyte et la détermination de la concentration du ou des analytes se trouvant dans l'échantillon. L'invention concerne également des formulations, des kits de parties, des systèmes et des procédés exécutés par ordinateur associés à ce procédé.
PCT/SG2014/000269 2014-02-28 2014-06-10 Dispositif d'analyse d'urine et réactif sec pour analyse quantitative de l'urine WO2015130225A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
KR1020207024160A KR102267988B1 (ko) 2014-02-28 2014-06-10 소변 검사 장치 및 정량적 소변 검사를 위한 건식 시약
CN201480076591.9A CN106255887B (zh) 2014-02-28 2014-06-10 用于定量尿液分析的尿液分析装置和干试剂
US15/121,808 US10436792B2 (en) 2014-02-28 2014-06-10 Urinalysis device and dry reagent for quantitative urinalysis
JP2016554178A JP6490090B2 (ja) 2014-02-28 2014-06-10 尿検査装置および定量的尿検査用乾燥試薬
KR1020207024161A KR102301688B1 (ko) 2014-02-28 2014-06-10 소변 검사 장치 및 정량적 소변 검사를 위한 건식 시약
AU2014384759A AU2014384759B2 (en) 2014-02-28 2014-06-10 Urinalysis device and dry reagent for quantitative urinalysis
MYPI2016001553A MY192493A (en) 2014-02-28 2014-06-10 Urinalysis device and dry reagent for quantitative urinalysis
EP14883985.5A EP3111228A4 (fr) 2014-02-28 2014-06-10 Dispositif d'analyse d'urine et réactif sec pour analyse quantitative de l'urine
KR1020167026791A KR102205101B1 (ko) 2014-02-28 2014-06-10 소변 검사 장치 및 정량적 소변 검사를 위한 건식 시약
SG11201606798QA SG11201606798QA (en) 2014-02-28 2014-06-10 Urinalysis device and dry reagent for quantitative urinalysis
US16/239,743 US10656160B2 (en) 2014-02-28 2019-01-04 Urinalysis device and dry reagent for quantitative urinalysis
US16/239,750 US10613097B2 (en) 2014-02-28 2019-01-04 Urinalysis device and dry reagent for quantitative urinalysis
AU2021204418A AU2021204418A1 (en) 2014-02-28 2021-06-28 Urinalysis device and dry reagent for quantitative urinalysis
AU2021204516A AU2021204516A1 (en) 2014-02-28 2021-06-30 Urinalysis device and dry reagent for quantitative urinalysis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461946228P 2014-02-28 2014-02-28
US61/946,228 2014-02-28

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/121,808 A-371-Of-International US10436792B2 (en) 2014-02-28 2014-06-10 Urinalysis device and dry reagent for quantitative urinalysis
US16/239,750 Division US10613097B2 (en) 2014-02-28 2019-01-04 Urinalysis device and dry reagent for quantitative urinalysis
US16/239,743 Division US10656160B2 (en) 2014-02-28 2019-01-04 Urinalysis device and dry reagent for quantitative urinalysis

Publications (1)

Publication Number Publication Date
WO2015130225A1 true WO2015130225A1 (fr) 2015-09-03

Family

ID=54009421

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/SG2014/000269 WO2015130225A1 (fr) 2014-02-28 2014-06-10 Dispositif d'analyse d'urine et réactif sec pour analyse quantitative de l'urine
PCT/SG2015/000064 WO2015130233A1 (fr) 2014-02-28 2015-03-02 Dispositif d'analyse d'urine pour analyse d'urine quantitative

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/SG2015/000064 WO2015130233A1 (fr) 2014-02-28 2015-03-02 Dispositif d'analyse d'urine pour analyse d'urine quantitative

Country Status (9)

Country Link
US (3) US10436792B2 (fr)
EP (1) EP3111228A4 (fr)
JP (3) JP6490090B2 (fr)
KR (3) KR102301688B1 (fr)
CN (1) CN106255887B (fr)
AU (3) AU2014384759B2 (fr)
MY (2) MY198081A (fr)
SG (4) SG11201606798QA (fr)
WO (2) WO2015130225A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105301171A (zh) * 2015-11-15 2016-02-03 常州大学 定硫仪中蜗传直线并行的氢氧化钠标定装置
WO2017078630A1 (fr) 2015-11-04 2017-05-11 Nitto Denko Corporation Appareil et système de distribution et/ou dosage d'échantillon de biofluide
EP3463058A4 (fr) * 2016-05-31 2020-01-22 Indian Institute of Technology, Guwahati Système/kit à base de transmittance pour la quantification au point d'intervention d'échantillons de biomarqueurs et son utilisation
US11460409B1 (en) * 2017-05-05 2022-10-04 Vision Diagnostics, Inc. Methods and reagents useful for verification of the integrity of a urine sample and the detection of counterfeit urine
US11493498B2 (en) 2018-12-20 2022-11-08 Vision Diagnostics, Inc. Assays and methods for diagnosing substance use disorder

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107091927B (zh) * 2017-06-28 2018-11-06 安徽惠邦生物工程有限公司 一种用于糖尿病肾病早期诊断的试剂盒
CN107132352B (zh) * 2017-07-07 2019-02-19 济南齐鲁医学检验有限公司 一种微量白蛋白肌酐比值(arc)检测装置
CN108169222A (zh) * 2017-12-14 2018-06-15 吉林省汇酉生物技术股份有限公司 一种检测尿液肌酐的试剂及其应用
CN108008125A (zh) * 2017-12-18 2018-05-08 江苏浩欧博生物医药股份有限公司 一种适用于免疫磁珠的冻干工作液和免疫磁珠冻干品及其制备方法
WO2019139980A1 (fr) * 2018-01-09 2019-07-18 Idexx Laboratories, Inc. Procédés de mesure d'un analyte et/ou d'une protéine dans des échantillons biologiques
CN108426875A (zh) * 2018-03-27 2018-08-21 山东五洲检测有限公司 一种用于检测食品中亚硫酸盐的试剂及其检测方法
EP3821056B1 (fr) 2018-07-13 2024-03-13 Siemens Healthcare Diagnostics, Inc. Indicateur de détection de dosage de microalbumine créatinine et procédé de production et d'utilisation associés
CN109187834A (zh) * 2018-08-20 2019-01-11 广州金域医学检验中心有限公司 一种空白尿液基质及其用途
CN109613274A (zh) * 2018-12-28 2019-04-12 上海高踪医疗器械科技有限公司 一种测定肌酐的试剂盒及方法
CN109596611A (zh) * 2019-01-21 2019-04-09 湖北紫荆生物技术有限公司 一种水体钙含量测试剂及水体钙含量测量方法
CN113728223A (zh) * 2019-01-25 2021-11-30 株式会社普欧威盖特 抗原的测定方法和测定装置
CN109916893A (zh) * 2019-04-12 2019-06-21 吉林省汇酉生物技术股份有限公司 一种定量检测白蛋白含量的干化学试剂片及其制备方法
CN111001452B (zh) * 2019-12-20 2022-04-05 京东方科技集团股份有限公司 一种微型全分析器件及其制作方法
USD975312S1 (en) 2020-02-14 2023-01-10 Beckman Coulter, Inc. Reagent cartridge
CZ309297B6 (cs) * 2020-08-11 2022-08-10 Meopta - Optika, S.R.O. Telecentrický f-theta objektiv s korigovanou chromatickou vadou pro laserové aplikace v UV oblasti
WO2024070995A1 (fr) * 2022-09-26 2024-04-04 富士フイルム株式会社 Réactif de mesure de l'albumine et procédé de mesure de l'albumine
WO2024096593A1 (fr) * 2022-11-01 2024-05-10 성균관대학교산학협력단 Détecteur de biomarqueur, son procédé de préparation et procédé de détection de biomarqueur
CN117805352A (zh) * 2023-12-28 2024-04-02 河北盛华尔生物医疗科技有限公司 一种稳定且抗干扰的血清白蛋白检测试剂盒

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705013A (en) * 1970-01-05 1972-12-05 Xerox Corp Analytical procedures and compositions therefor
US4111657A (en) * 1977-01-21 1978-09-05 American Monitor Corporation Creatinine assay and reagent system
WO1984003948A1 (fr) * 1983-04-07 1984-10-11 American Monitor Corp Composition amelioree de reactif et analyse pour la determination de creatinine
WO1988010429A1 (fr) * 1987-06-26 1988-12-29 Beckman Instruments, Inc. Reactif a base de liquide froid stable reagissant a la creatinine
US5558834A (en) * 1991-10-03 1996-09-24 Bayer Corporation Device and method of seperating and assaying whole blood
EP1362925A1 (fr) * 2001-01-31 2003-11-19 Asahi Kasei Kabushiki Kaisha Compositions pour analyse de glycoproteines
CN101221183A (zh) * 2007-01-12 2008-07-16 广东省药品检验所 一种鉴别人血白蛋白制品的方法
CN103278648A (zh) * 2013-05-24 2013-09-04 宁波美康生物科技股份有限公司 一种白蛋白检测试剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3533749A (en) * 1967-09-12 1970-10-13 Warner Lambert Pharmaceutical Method for the determination of total albumin
US3894843A (en) 1974-03-04 1975-07-15 Coulter Diagnostics Inc Determination of serum creatinine
JPS5529718A (en) * 1978-08-23 1980-03-03 Hitachi Ltd Creatinine analysis method
US4330296A (en) * 1980-06-23 1982-05-18 Beckman Instruments, Inc. Albumin reagent and assay
JPH0245827B2 (ja) * 1982-04-02 1990-10-11 Shino Test Corp Kureachininsokuteiyoshakusoseibutsu
US4568647A (en) * 1983-10-11 1986-02-04 Eastman Kodak Company Method and element for albumin assay
DE3774570D1 (fr) * 1987-04-22 1991-12-19 Pharmacia Diagnostics Inc., Fairfield, N.J., Us
JPH0668494B2 (ja) 1987-08-20 1994-08-31 富士写真フイルム株式会社 アルブミン分析用一体型多層分析要素
US5194390A (en) 1988-07-05 1993-03-16 Miles Inc. Composition for the assay of albumin
FI91777C (fi) * 1990-04-02 1994-08-10 Elomit Oy Menetelmä plasmiiniaktiivisuuden määrittämiseksi
US6468805B1 (en) * 1990-10-10 2002-10-22 Chimera Research And Chemical Inc. Automated analyzer testing of urine for presence of a pH abnormality
US5334503A (en) * 1991-10-08 1994-08-02 Eastman Kodak Company Test kit and method for the detection of microorganisms associated with periodontal diseases using surfactant mixture as extraction composition
US5268146A (en) 1992-03-25 1993-12-07 Litmus Concepts, Inc. Fast response test panel
JP3516002B2 (ja) * 1995-08-29 2004-04-05 アークレイ株式会社 クレアチニン測定用試験片
US6194394B1 (en) * 1998-07-01 2001-02-27 Sigma-Aldrich Co. Coagulation controls for prothrombin time (PT) and activated partial thromboplastin time (APTT) assays
AU5223899A (en) * 1998-07-27 2000-02-21 Ljl Biosystems, Inc. Apparatus and methods for spectroscopic measurements
WO2001046679A1 (fr) * 1999-12-22 2001-06-28 Applied Optics Center Of Delaware, Inc. Procede et dispositif d'analyse d'echantillons dans un analyseur clinique utilisant un rayonnement coherent
SE0001453D0 (sv) 2000-04-19 2000-04-19 Astrazeneca Ab Method of monitoring a freeze drying process
JP4214271B2 (ja) 2002-10-15 2009-01-28 アークレイ株式会社 クレアチニン測定用試験片
US7445908B2 (en) * 2003-06-18 2008-11-04 The United States Of America As Represented By The Secretary Of The Army Detection of oxidizing agents in urine
US20110070574A1 (en) * 2008-06-02 2011-03-24 Ge Healthcare Bio-Sciences Ab Method for virus detection
KR101257299B1 (ko) * 2009-09-09 2013-04-22 한국전자통신연구원 휴대형 배뇨 분석용 디지털 리더기
US8476081B2 (en) 2009-09-21 2013-07-02 Janssen Pharmaceutica Nv Assay for evaluating affinity and specificity of ligand-albumin binding
JP5363631B2 (ja) * 2011-09-28 2013-12-11 富士フイルム株式会社 蛍光粒子を用いた検出対象物質の検出方法
US20130344120A1 (en) * 2012-06-21 2013-12-26 Douglas Craig Scott Mouth Rinse Emulsions

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705013A (en) * 1970-01-05 1972-12-05 Xerox Corp Analytical procedures and compositions therefor
US4111657A (en) * 1977-01-21 1978-09-05 American Monitor Corporation Creatinine assay and reagent system
WO1984003948A1 (fr) * 1983-04-07 1984-10-11 American Monitor Corp Composition amelioree de reactif et analyse pour la determination de creatinine
WO1988010429A1 (fr) * 1987-06-26 1988-12-29 Beckman Instruments, Inc. Reactif a base de liquide froid stable reagissant a la creatinine
US5558834A (en) * 1991-10-03 1996-09-24 Bayer Corporation Device and method of seperating and assaying whole blood
EP1362925A1 (fr) * 2001-01-31 2003-11-19 Asahi Kasei Kabushiki Kaisha Compositions pour analyse de glycoproteines
CN101221183A (zh) * 2007-01-12 2008-07-16 广东省药品检验所 一种鉴别人血白蛋白制品的方法
CN103278648A (zh) * 2013-05-24 2013-09-04 宁波美康生物科技股份有限公司 一种白蛋白检测试剂

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
B ACON ET AL.: "Kinetic Study of the Jaffe Reaction for Quantifying Creatinine in Serum: 2. Evaluation of Buffered Reagent and Comparison of Different Data-Processing Options", CLINICAL CHEMISTRY, vol. 35, no. 3, 1989, pages 360 - 363, XP055220809 *
DATABASE WPI Week 200878, Derwent World Patents Index; Class a89, AN 2008-N25187, ACCESSION *
DATABASE WPI Week 201426, Derwent World Patents Index; Class A89, AN 2013-v41898, ACCESSION *
NOZAKI Y. ET AL.: "The Interaction of a Cationic Detergent with Bovine Serum Albumin and Other Proteins", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 249, no. 14, 1974, pages 4452 - 4459, XP055220812 *
SCHIFREEN ET AL.: "Diethylamine Prevents Precipitation in the Alkaline Buffer Reagent for the Kinetic Jaffe Determination of Serum Creatinine", CLINICAL CHEMISTRY, vol. 27, no. 1, 1981, pages 196 - 197, XP055220811 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017078630A1 (fr) 2015-11-04 2017-05-11 Nitto Denko Corporation Appareil et système de distribution et/ou dosage d'échantillon de biofluide
US11376594B2 (en) 2015-11-04 2022-07-05 Nitto Denko Corporation Apparatus and system for biofluid sample dispensing and/or assay
CN105301171A (zh) * 2015-11-15 2016-02-03 常州大学 定硫仪中蜗传直线并行的氢氧化钠标定装置
EP3463058A4 (fr) * 2016-05-31 2020-01-22 Indian Institute of Technology, Guwahati Système/kit à base de transmittance pour la quantification au point d'intervention d'échantillons de biomarqueurs et son utilisation
US11460409B1 (en) * 2017-05-05 2022-10-04 Vision Diagnostics, Inc. Methods and reagents useful for verification of the integrity of a urine sample and the detection of counterfeit urine
US11493498B2 (en) 2018-12-20 2022-11-08 Vision Diagnostics, Inc. Assays and methods for diagnosing substance use disorder
US11493497B1 (en) 2018-12-20 2022-11-08 Vision Diagnostics, Inc. Assays and methods for diagnosing substance use disorder

Also Published As

Publication number Publication date
CN106255887A (zh) 2016-12-21
JP6703569B2 (ja) 2020-06-03
AU2021204418A1 (en) 2021-07-22
JP2017514107A (ja) 2017-06-01
KR20200104921A (ko) 2020-09-04
AU2021204516A1 (en) 2021-07-29
WO2015130233A1 (fr) 2015-09-03
AU2014384759A1 (en) 2016-09-29
KR102205101B1 (ko) 2021-01-19
US10656160B2 (en) 2020-05-19
US20170010276A1 (en) 2017-01-12
MY192493A (en) 2022-08-24
KR20200104920A (ko) 2020-09-04
US20190187146A1 (en) 2019-06-20
JP6490090B2 (ja) 2019-03-27
KR20160135737A (ko) 2016-11-28
CN106255887B (zh) 2018-12-07
KR102301688B1 (ko) 2021-09-13
JP6703568B2 (ja) 2020-06-03
SG10201913420XA (en) 2020-03-30
MY198081A (en) 2023-07-31
US10436792B2 (en) 2019-10-08
SG10201913417QA (en) 2020-03-30
JP2018185335A (ja) 2018-11-22
SG11201606798QA (en) 2016-09-29
AU2014384759B2 (en) 2021-07-22
KR102267988B1 (ko) 2021-06-22
US20190187147A1 (en) 2019-06-20
JP2018185334A (ja) 2018-11-22
SG10201913421YA (en) 2020-03-30
EP3111228A4 (fr) 2017-11-08
EP3111228A1 (fr) 2017-01-04
US10613097B2 (en) 2020-04-07

Similar Documents

Publication Publication Date Title
US10613097B2 (en) Urinalysis device and dry reagent for quantitative urinalysis
EP3301433B1 (fr) Procédé d'étalonnage pour analyseur de carte de réactif
JP2009109196A (ja) 希釈倍率導出方法、定量方法、及び分析装置
US7691255B2 (en) Sensor, measuring device, and measuring method
CA2907517A1 (fr) Procede d'etalonnage pour photometrie
CN101680876A (zh) 全血检测
Pokhrel et al. Selection of appropriate protein assay method for a paper microfluidics platform
US10458963B2 (en) Quantitative HPTLC cannabinoid field testing device and method
JP5079312B2 (ja) 在庫情報を使った液体の有用時間の決定
AU2004218604B2 (en) On-board control for analytical elements
CN101477059B (zh) 快速检测水溶液中无机磷的方法
US20160157836A1 (en) Systems and methods to determine body drug concentration from an oral fluid
Gaikwad et al. Use of stopped-flow fluorescence polarization immunoassay in drug determinations
EP1754062A1 (fr) Systeme de dosage avec formation in situ de reactif diazo
CN108169222A (zh) 一种检测尿液肌酐的试剂及其应用
Gaikwad et al. Estimation of opiates in urine by stopped-flow fluorimmunoassay
JP2009109428A (ja) 希釈用水溶液、試薬、及び希釈度算出方法、定量方法、分析用デバイス、測定キット、および分析装置
WO2017142813A1 (fr) Systèmes et méthodes de détermination de la concentration d'une drogue dans l'organisme à partir d'un prélèvement buccal
JPS6073360A (ja) 自動分析装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14883985

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2016554178

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15121808

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: IDP00201606429

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 20167026791

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014883985

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014883985

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014384759

Country of ref document: AU

Date of ref document: 20140610

Kind code of ref document: A